OA03.01 A Non-Randomized, Open-Label, Prospective, Multicenter Study of Apatinib as Second-Line and Later-Line Therapy in Patients with ES-SCLC
Xi Peng(Chengdu University), Min Chen, Q. Liu(Wuxi Fourth People's Hospital), L. Zhang(Wannan Medical College), Ye Gu(Changshu No.1 People's Hospital), Junying Xu(Wuxi People's Hospital), Y. Li(Xuzhou Medical College), Yingli Shang(Shandong Agricultural University), Jun Hua(Kennedy Krieger Institute), Jingyi Wu(Changshu No.1 People's Hospital), Yadan Xu(Nanfang Hospital), Li Deng(Capital Medical University), Jie Tan(Hunan Normal University), T. Zhou(Children's Oncology Group), X. Pu(Hunan Cancer Hospital)
Cited by 2
Related Papers
Temozolomide in the treatment of children with newly diagnosed diffuse intrinsic pontine gliomas: a report from the Children's Oncology Group
|Neuro-Oncology|2011|342
Nuclear Overhauser enhancement (NOE) imaging in the human brain at 7T
|NeuroImage|2013|327
The IFN-γ/PD-L1 axis between T cells and tumor microenvironment: hints for glioma anti-PD-1/PD-L1 therapy
|Journal of Neuroinflammation|2018|268
Role of Notch signaling in regulating innate immunity and inflammation in health and disease
|Protein & Cell|2016|245
Quantitative description of the asymmetry in magnetization transfer effects around the water resonance in the human brain
|Magnetic Resonance in Medicine|2007|220